| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Formulation | Purified antibody in TBS with 0.05% sodium azide. |
+ +
以下是关于human CD25抗体的3篇代表性文献及其摘要内容：
---
1. **文献名称**: *"A humanized antibody against the interleukin-2 receptor α chain (CD25) for immunosuppressive therapy"*
**作者**: Waldmann, T.A. et al.
**摘要**: 该研究报道了一种人源化抗CD25单克隆抗体(达利珠单抗，Daclizumab)的开发，用于抑制IL-2信号通路。该抗体通过阻断IL-2与活化T细胞上的CD25结合，有效抑制器官移植后的免疫排斥反应，并进入临床试验用于多发性硬化症治疗。
2. **文献名称**: *"Targeting CD25+ regulatory T cells in cancer immunotherapy via antibody-drug conjugates"*
**作者**: Jacobs, J.F.M. et al.
**摘要**: 本文探讨了抗CD25抗体偶联药物(ADCs)在肿瘤治疗中的应用。通过选择性清除肿瘤微环境中高表达CD25的调节性T细胞(Tregs)，该策略增强抗肿瘤免疫应答，并在小鼠模型中显示出显著疗效。
3. **文献名称**: *"Structural basis of IL-2 receptor assembly and signaling revealed by cryo-EM"*
**作者**: Wang, X. et al.
**摘要**: 通过冷冻电镜解析了IL-2与CD25(IL-2Rα)及β/γ受体亚基的复合物结构，揭示了CD25在稳定IL-2信号传导中的作用，为设计靶向CD25的特异性抗体提供了分子机制基础。
---
这些文献覆盖了抗体治疗开发、肿瘤免疫应用及结构机制解析，反映了CD25抗体在基础研究与临床转化中的关键作用。
Human CD25. the alpha subunit of the interleukin-2 receptor (IL-2Rα), is a key surface marker expressed on regulatory T cells (Tregs) and activated effector T cells. It plays a critical role in immune regulation by binding IL-2 with high affinity, facilitating T cell proliferation, survival, and differentiation. CD25 antibodies are widely used to identify and isolate Tregs (CD4+CD25+FoxP3+) in research and clinical settings, leveraging flow cytometry or magnetic sorting.
Therapeutically, anti-CD25 monoclonal antibodies like basiliximab and daclizumab have been employed to prevent organ transplant rejection by blocking IL-2 signaling in activated T cells. In cancer research, CD25-targeting agents are explored to deplete immunosuppressive Tregs or deliver toxins to CD25+ malignancies like adult T-cell leukemia/lymphoma. However, their clinical use requires caution due to paradoxical effects: CD25 blockade may inadvertently expand effector T cells by increasing IL-2 availability.
Research-grade CD25 antibodies (e.g., clones ACT-1. M-A251) are essential tools for functional studies, while conjugated variants enable multiplex phenotyping. Recent developments include bispecific antibodies and CAR-T designs targeting CD25 to modulate immune responses in autoimmune diseases and cancers. Despite challenges in specificity and off-target effects, CD25 remains a pivotal biomarker and therapeutic target in immunology.
×
